Cidara Therapeutics (CDTX) Competitors $88.58 +15.09 (+20.53%) Closing price 04:00 PM EasternExtended Trading$87.93 -0.65 (-0.73%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, CRSP, and TGTXShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), CRISPR Therapeutics (CRSP), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics TG Therapeutics Cidara Therapeutics (NASDAQ:CDTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Do insiders & institutionals believe in CDTX or RYTM? 35.8% of Cidara Therapeutics shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, CDTX or RYTM? Cidara Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500. Do analysts prefer CDTX or RYTM? Cidara Therapeutics currently has a consensus price target of $105.43, indicating a potential upside of 19.02%. Rhythm Pharmaceuticals has a consensus price target of $104.50, indicating a potential upside of 7.83%. Given Cidara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cidara Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Is CDTX or RYTM more profitable? Cidara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Cidara Therapeutics' return on equity of -50.81% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -50.81% -42.46% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Does the media favor CDTX or RYTM? In the previous week, Cidara Therapeutics and Cidara Therapeutics both had 14 articles in the media. Rhythm Pharmaceuticals' average media sentiment score of 1.42 beat Cidara Therapeutics' score of 0.71 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, CDTX or RYTM? Cidara Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M1,768.81-$169.83M-$11.13-7.96Rhythm Pharmaceuticals$130.13M49.46-$260.60M-$3.01-32.20 SummaryCidara Therapeutics beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.25B$3.11B$5.74B$10.35BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-7.9620.9076.3526.43Price / Sales1,768.81254.49466.9890.96Price / CashN/A46.3537.4661.85Price / Book5.949.8313.186.39Net Income-$169.83M-$52.73M$3.29B$271.22M7 Day Performance36.59%4.85%2.50%2.79%1 Month Performance33.46%6.37%4.60%7.35%1 Year Performance722.47%19.15%73.81%29.74% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics3.9207 of 5 stars$88.58+20.5%$105.43+19.0%+576.1%$2.25B$1.27M-7.9690News CoverageAnalyst ForecastGap UpHigh Trading VolumeRYTMRhythm Pharmaceuticals3.4833 of 5 stars$96.03-0.2%$101.57+5.8%+93.3%$6.39B$156.29M-31.90140Positive NewsAnalyst ForecastABVXAbivax2.5619 of 5 stars$85.87+2.2%$99.43+15.8%+655.2%$6.35BN/A0.0061Gap UpCYTKCytokinetics4.222 of 5 stars$49.44-3.3%$75.38+52.5%-6.8%$6.12B$18.47M-9.69250Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.1558 of 5 stars$33.88+2.3%$74.22+119.1%-28.3%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.8911 of 5 stars$116.78-1.4%$177.86+52.3%+29.1%$5.91B$495.03M-23.03380Positive NewsInsider TradeNUVLNuvalent3.1071 of 5 stars$79.37-1.4%$120.91+52.3%-20.5%$5.80BN/A-16.2040RNAAvidity Biosciences2.0524 of 5 stars$40.22-10.1%$68.94+71.4%-2.8%$5.76B$10.90M-11.30190Analyst ForecastMRUSMerus3.1658 of 5 stars$68.09-2.1%$88.75+30.3%+42.8%$5.26B$36.13M-12.3837Positive NewsCRSPCRISPR Therapeutics3.1896 of 5 stars$57.84+2.8%$71.60+23.8%+30.0%$5.12B$37.31M-10.65460Analyst ForecastTGTXTG Therapeutics4.3521 of 5 stars$31.75-1.3%$46.25+45.7%+53.0%$5.10B$454.07M85.81290 Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors Abivax Competitors Cytokinetics Competitors Legend Biotech Competitors Axsome Therapeutics Competitors Nuvalent Competitors Avidity Biosciences Competitors Merus Competitors CRISPR Therapeutics Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDTX Stock Alerts